A.R.T. Advisors LLC Invests $807,000 in Tetraphase Pharmaceuticals Inc. (TTPH)

Share on StockTwits

A.R.T. Advisors LLC bought a new position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 262,896 shares of the biopharmaceutical company’s stock, valued at approximately $807,000. A.R.T. Advisors LLC owned approximately 0.51% of Tetraphase Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TTPH. Schwab Charles Investment Management Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 12.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 243,869 shares of the biopharmaceutical company’s stock worth $1,537,000 after purchasing an additional 26,790 shares in the last quarter. BlackRock Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 21.2% during the fourth quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock worth $25,479,000 after purchasing an additional 707,296 shares in the last quarter. AXA increased its stake in shares of Tetraphase Pharmaceuticals by 7.1% during the fourth quarter. AXA now owns 216,337 shares of the biopharmaceutical company’s stock worth $1,363,000 after purchasing an additional 14,400 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Tetraphase Pharmaceuticals by 77.6% during the fourth quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock worth $3,733,000 after purchasing an additional 258,908 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Tetraphase Pharmaceuticals by 168.6% during the fourth quarter. Deutsche Bank AG now owns 221,425 shares of the biopharmaceutical company’s stock worth $1,394,000 after purchasing an additional 138,996 shares in the last quarter. 44.60% of the stock is owned by institutional investors and hedge funds.

Shares of Tetraphase Pharmaceuticals opened at $3.55 on Thursday, according to MarketBeat Ratings. Tetraphase Pharmaceuticals Inc. has a 12-month low of $2.05 and a 12-month high of $8.75. The stock has a market cap of $200.19 million, a P/E ratio of -1.35 and a beta of 2.64.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.04. The company had revenue of $1.89 million during the quarter, compared to analysts’ expectations of $1.88 million. Tetraphase Pharmaceuticals had a negative net margin of 1,061.06% and a negative return on equity of 85.70%. equities analysts expect that Tetraphase Pharmaceuticals Inc. will post -1.56 earnings per share for the current year.

A number of research firms have recently commented on TTPH. ValuEngine raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 4th. Gabelli raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 29th. BMO Capital Markets reaffirmed a “market perform” rating and set a $3.00 price objective (up previously from $2.75) on shares of Tetraphase Pharmaceuticals in a research note on Thursday, March 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, March 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $7.22.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH).

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply